Reditux 100 (Rituximab) 100 mg
Reditux 100 (Rituximab 100 mg/10 ml) is a monoclonal antibody therapy targeting CD20 antigen.
Manufacturer: Dr. Reddy's Laboratories. Reditux is the world's first approved biosimilar of MabThera (Rituxan), offering proven efficacy and safety at a more accessible price.
Mechanism of Action ("Targeted Destruction"):
Rituximab binds specifically to the CD20 antigen located on pre-B and mature B lymphocytes. Once bound, it flags these cells for destruction by the body's own immune system (cell-mediated cytotoxicity). It acts like a guided missile against cancerous B-cells.
✅ Key Benefit: Standard of care for many B-cell malignancies and autoimmune diseases.
Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 18.03.2026
Similar products
What Customers Say
No reviews yet
Your review can be the first!